Incremental and Decremental PEEP Titration by Diverse Strategies in Subjects With ARDS: A Prospec… (NCT06808438) | Clinical Trial Compass
CompletedNot Applicable
Incremental and Decremental PEEP Titration by Diverse Strategies in Subjects With ARDS: A Prospective Physiological Study
China31 participantsStarted 2023-10-01
Plain-language summary
The investigators conducted a prospective physiological observation study on ARDS population, described their physiological and EIT indexes with various PEEP titration methods, and also compared and analyzed those indexes to determine whether there were differences among various PEEP titration methods.The objective of this study was to explore and uncover the physiological differences in response to optimal PEEP in different ways,and analyzed the correlation of the optimal PEEP in these different ways.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Intubated and mechanical ventilated patients in ICU within 48 hours
* Be over 18 years old
* With moderate-severe ARDS (PaO2 /FIO2 ,200 mm Hg)
Exclusion Criteria:
* Severe chronic obstructive pulmonary diseases
* Pulmonary bulla(\>1CM) or pneumothorax or pneumomediastinum or subcutaneous emphysema
* Pregnancy
* BMI≥35kg/m2
* Suspected pulmonary vascular hemorrhage
* Disturbance of consciousness or intracranial hypertension
* Severe cardiac dysfunction (New York Heart Association Class III or IV, acute -Coronary syndrome or persistent ventricular tachyarrhythmia), cardiogenic shock or after major cardiac surgery
* Hemodynamic instability (i.e., mean arterial pressure \[MAP\]\<60 mm Hg despite vasopressor use
* The medical team considering short periods of high pressure to be unsafe
* Contraindications for placement of esophageal pressure catheters (e.g., esophageal varix or fracture of skull base)
* Contraindications for EIT monitoring (including pacemaker, or cutaneous diseases which limiting electrode placement)
* Agonal stage or end-stages of diseases
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
the selected PEEP values
Timeframe: through study completion, an average of 1 year